Prognostic Factors and Predictors of Disease Flare in Patients With Rheumatoid Arthritis

NCT07381296 · tracked via the Priya Life Science Egypt tracker

Sponsor

Sohag University

Phase

Observational

Started

2026-02-01

Last updated

2026-05-19

Condition(s) studied

Rheumatoid Arthritis Disease Flare

Investigational drug(s) / intervention(s)

Clinical and Laboratory Monitoring for RA Disease Flare

Clinical and Laboratory Monitoring for RA Disease Flare: This is an observational study; no new clinical interventions or experimental drugs will be administered. All patients will continue their standard-of-care treatment as prescribed by their treating rheumatologist. The study involves scheduled clinical and laboratory monitoring every three months to identify predictors of rheumatoid arthritis (RA) flares. Data collection includes: Clinical assessments: Joint counts (TJC/SJC), Patient/Evaluator Global Assessments, and disease activity scores (DAS28, SDAI, CDAI). Laboratory monitoring: Complete Blood Count (CBC) to calculate systemic inflammatory indices (NLR, PLR, SII, SIRI, and PIV) and acute phase reactants (ESR, CRP). Radiographic evaluation: Assessment of joint damage using the modified Sharp scoring system.

Study summary

The goal of this observational study is to help find better ways to predict when a flare of your disease (rheumatoid arthritis) might happen. By looking at your registered data, symptoms, disease characteristics, and specific markers in your blood, the investigators hope to help doctors make better decisions about your treatment in the future. The main question it aims to answer is:

Can specific patient data, disease characteristics, drug history, or markers in a patient's blood be used to predict when a rheumatoid arthritis flare is about to happen? Participants already diagnosed with rheumatoid arthritis and who have their disease controlled will be followed up every 3 months for any signs or symptoms of a flare.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Accepted

Inclusion Criteria: * Age: patients \>18 years old. * Patients with rheumatoid arthritis diagnosed according to the 2010 American College of Rheumatology (ACR)/European Alliance of Associations for Rheumatology Classification Criteria for RA. * Clinical remission or low disease activity according to the disease activity score in 28 joints (DAS28). Exclusion Criteria: * Age \< 18 years. * Any autoimmune disease other than Rheumatoid arthritis. Severe infection, pregnancy, and malignancy.

Primary outcome measure(s)

Correlation between Systemic Inflammation Ratios and Disease Flares — Every 3 months for a total of 17 months (from February 2026 to June 2027).
Evaluation of blood-cell-derived inflammatory indices including Neutrophil/Lymphocyte Ratio (NLR), Systemic Immune-inflammation Index (SII), and Pan-Immune-Inflammation Value (PIV). These will be calculated from CBC results to determine their sensitivity and specificity in predicting a clinical flare.

Trial sites (1)

Facility	City	Region	Status
Rheumatology and Rehabilitation Department, Faculty of Medicine, Sohag University	Sohag	Sohag Governorate	Recruiting

More Sohag University trials in Egypt

Colitis Patterns in Patients With Lower GI Symptoms Starting soon

Zadek Osteotomy for Treatment of Haglund's Syndrome Recruiting

Effects of Dexmedetomidine Combined With Lidocaine Topical Administration on Cough Reflex During Extubation in Thyroidectomy Patient. Active, not recruiting

Toxoplasma Gondii Seroprevalence Among Children With Some Neuropsychiatric Disorders Starting soon

Accuracy of Transabdominal Ultrasound in Predicting Intraperitoneal Adhesions Prior to Laparoscopy Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07381296 on ClinicalTrials.gov ↗ ← All trials in Egypt